The Re-Qualification of the asthma patient on Biologic therapy (ReQualBi) study has highlighted the importance of verifying prior diagnoses in patients with SA in whom HE persists despite therapy with anti-IL-5/5R MAbs, or in whom continued eosinophilia persists despite daily OCSs. The gene discussed is IL5; the disease is hereditary elliptocytosis.